These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Measures to reduce the serum lipid levels in coronary heart disease. Connor WE Med Clin North Am; 1968 Sep; 52(5):1249-60. PubMed ID: 4876837 [No Abstract] [Full Text] [Related]
26. Diet and drugs in the treatment of hyperlipidemias. Med Lett Drugs Ther; 1970 May; 12(10):42-4. PubMed ID: 5514225 [No Abstract] [Full Text] [Related]
27. [Effects of diet changes and use of dextrothyroxine and chlorphenisate on serum lipids]. Arteaga A; Cisternas H; Torres MC; Alliende ME Rev Med Chil; 1969 May; 97(5):285-90. PubMed ID: 5386042 [No Abstract] [Full Text] [Related]
28. [Comparative evaluation of treatment of patients with coronary atherosclerosis with nicatol and nicotinic acid]. Ivanchenko FT Vrach Delo; 1967 Jan; 1():76-80. PubMed ID: 4895148 [No Abstract] [Full Text] [Related]
29. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. Coronary Drug Project Research Group N Engl J Med; 1977 May; 296(21):1185-90. PubMed ID: 323705 [TBL] [Abstract][Full Text] [Related]
30. Vascular symptomatic relief during administration of ethylchlorophenoxyisobutyrate (clofibrate). Albert M; Stansell MJ Metabolism; 1969 Aug; 18(8):635-45. PubMed ID: 4895062 [No Abstract] [Full Text] [Related]
31. [Medical treatment of hyperlipemia. Indications and modern preparations]. Frey H Tidsskr Nor Laegeforen; 1968 Jan; 88(2):6-8. PubMed ID: 5663311 [No Abstract] [Full Text] [Related]
32. Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease. Rosenhamer G; Carlson LA Atherosclerosis; 1980 Sep; 37(1):129-42. PubMed ID: 7426081 [No Abstract] [Full Text] [Related]
33. Editorial: Results of the coronary drug project--an interpretation. Carlson LA; Rössner S Atherosclerosis; 1975; 22(3):317-23. PubMed ID: 1106450 [No Abstract] [Full Text] [Related]
34. Clofibrate and coronary heart disease. Med J Aust; 1972 Jan; 1(4):145-7. PubMed ID: 4551814 [No Abstract] [Full Text] [Related]
35. Diet and drug therapy for hyperlipoproteinemia. Maha GE Med Times; 1971 Aug; 99(8):49-63 passim. PubMed ID: 5566828 [No Abstract] [Full Text] [Related]
36. [Use of cetamiphen and nicotinic acid in the treatment of patients with coronary atherosclerosis]. Savenkov PM Kardiologiia; 1967 Apr; 7(4):50-3. PubMed ID: 5598475 [No Abstract] [Full Text] [Related]
37. Coronary drug project. Caceres CA; Enslein K JAMA; 1978 Jun; 239(25):2655-6. PubMed ID: 349180 [No Abstract] [Full Text] [Related]
38. Type IIa hyperlipoproteinaemia. An evaluation of four therapeutic regimens. Watermeyer GS; Mann JI; Truswell AS; Levy I S Afr Med J; 1975 Apr; 49(15):631-4. PubMed ID: 1094562 [TBL] [Abstract][Full Text] [Related]
39. Aspirin in coronary heart disease. The Coronary Drug Project Research Group. J Chronic Dis; 1976 Oct; 29(10):625-42. PubMed ID: 789390 [TBL] [Abstract][Full Text] [Related]
40. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Dewar HA; Oliver MF Br Med J; 1971 Dec; 4(5790):784-6. PubMed ID: 4943607 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]